Lupin launches Propranolol long-acting capsules to improve heart health in Canada, ET HealthWorld

[ad_1]

Montreal: Lupin Pharma Canada Ltd., a wholly-owned subsidiary of Lupin Limited (Lupin), announced the introduction of Propranolol LA (long-acting) capsules in Canada. These capsules are available in four different strengths: 60 mg, 80 mg, 120 mg, and 160 mg.

Propranolol LA serves as a generic counterpart to Inderal® LA and offers an effective treatment option subsequent to the discontinuation of Inderal® LA. This launch of Propranolol LA is aimed at addressing the medical needs of patients in Canada, underscoring Lupin’s dedication to improving healthcare accessibility and affordability.

The introduction of Propranolol LA, the singular extended-release form of Propranolol accessible to Canadian patients post the discontinuation of Inderal® LA, has resulted in noteworthy advancements in meeting the unfulfilled requirements of patients. This extended-release version not only ensures a consistent mitigation of symptoms but also bolsters patient compliance and overall quality of life.

“We are delighted to announce the launch of Propranolol LA capsules for patients in Canada. We have diligently worked to build our portfolio to include Propranolol LA ensuring patients have access to the essential medicines. This launch signifies our commitment to fostering healthcare solutions that truly make a difference,” said Dr Sofia Mumtaz, President,Legal, Canada, Australia, and Japan, Lupin.

  • Published On Aug 30, 2023 at 06:15 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles


Scan to download App


[ad_2]

Leave a Reply

Your email address will not be published. Required fields are marked *